drugs – Benefits Canada.com https://www.benefitscanada.com Canada's most influential pension and benefits publication for decision-makers Fri, 15 Nov 2024 20:19:19 +0000 en-US hourly 1 https://wordpress.org/?v=4.9.8 Cancer treatments represented a third of medicines in clinical trials in 2023: report https://www.benefitscanada.com/benefits/health-benefits/cancer-treatments-represented-a-third-of-medicines-in-clinical-trials-in-2023-report/ Fri, 15 Nov 2024 14:00:04 +0000 https://www.benefitscanada.com/?p=162782 Cancer treatments represented 33 per cent of medicines in all phases of clinical trials in 2023, followed by treatments for infectious diseases (13 per cent) and central nervous system diseases (12 per cent), according to a new report by the Patented Medicine Prices Review Board. It found more than 12,000 new medicines were undergoing clinical […]

The post Cancer treatments represented a third of medicines in clinical trials in 2023: report appeared first on Benefits Canada.com.

]]> Canadian insurers paid out record $128BN in health, retirement benefits in 2023: CLHIA https://www.benefitscanada.com/news/bencan/canadian-insurers-paid-out-record-128bn-in-health-retirement-benefits-in-2023-clhia/ Thu, 03 Oct 2024 19:00:15 +0000 https://www.benefitscanada.com/?p=160845 Canada’s life and health insurers paid out a record $128 billion in health and retirement benefits last year, up from $114 billion in 2022, according to the Canadian Life and Health Insurance Association’s annual fact book. “The benefits that life and health insurers provide through workplace plans and individual policies contributed significantly to Canadians’ health […]

The post Canadian insurers paid out record $128BN in health, retirement benefits in 2023: CLHIA appeared first on Benefits Canada.com.

]]> Benefits use, plan sustainability top of mind for major Canadian employers: 2024 BCHS report launch https://www.benefitscanada.com/benefits/health-benefits/benefits-use-plan-sustainability-top-of-mind-for-major-canadian-employers-2024-bchs-report-launch/ Thu, 26 Sep 2024 13:00:43 +0000 https://www.benefitscanada.com/?p=160407 The 2024 Benefits Canada Healthcare Survey highlighted the perfect storm plan sponsors are facing: trying to strike the right balance between competitive benefits and plan sustainability. It’s something that resonates with the benefits leads of three major Canadian employers, who said during Benefits Canada’s report launch event that benefits utilization and meeting the needs of a […]

The post Benefits use, plan sustainability top of mind for major Canadian employers: 2024 BCHS report launch appeared first on Benefits Canada.com.

]]> Diabetes medications remain leading drug category for eligible claims in 2023: report https://www.benefitscanada.com/benefits/health-benefits/diabetes-medications-remain-leading-drug-category-for-eligible-claims-in-2023-report/ Wed, 24 Apr 2024 13:00:23 +0000 https://www.benefitscanada.com/?p=154574 In 2023, diabetes medications remained the leading drug category for eligible private insurance claims for the second consecutive year, according to Telus Health’s annual drug trends report. The report, based on claims data from more than 15 million plan members in 2023, found the growing prevalence of diabetes, along with expanded heart failure treatment indications and […]

The post Diabetes medications remain leading drug category for eligible claims in 2023: report appeared first on Benefits Canada.com.

]]> Highest-cost drugs reimbursed by Canadian public plans in 2021/22 were rare disease treatments: report https://www.benefitscanada.com/benefits/health-benefits/highest-cost-drugs-reimbursed-by-canadian-public-plans-in-2021-22-were-rare-disease-treatments-report/ Tue, 09 Jan 2024 14:00:15 +0000 https://www.benefitscanada.com/?p=149971 The 10 highest-cost drugs reimbursed by public drug plans in Canada in the 2021/22 fiscal year were all rare disease treatments with annual treatment costs of more than $250,000, according to a new report by the Patented Medicine Prices Review Board. It found the increased use of high-cost drugs continued to be the main factor […]

The post Highest-cost drugs reimbursed by Canadian public plans in 2021/22 were rare disease treatments: report appeared first on Benefits Canada.com.

]]> Survey finds a quarter of U.S. employers provide coverage of diabetes management drugs for weight loss https://www.benefitscanada.com/benefits/health-benefits/a-quarter-of-u-s-employers-providing-coverage-of-diabetes-management-drugs-for-weight-loss-survey/ Mon, 20 Nov 2023 14:00:49 +0000 https://www.benefitscanada.com/?p=147372 While three-quarters (76 per cent) of U.S. employers say they provide coverage of glucagon-like peptide-1 drugs for diabetes management, about a quarter (27 per cent) provide coverage of these drugs for weight loss, according to a new survey by the International Foundation of Employee Benefit Plans. The survey, which polled more than 200 U.S. benefits […]

The post Survey finds a quarter of U.S. employers provide coverage of diabetes management drugs for weight loss appeared first on Benefits Canada.com.

]]> 54% of benefits plan members currently live with at least one chronic condition: survey https://www.benefitscanada.com/benefits/health-wellness/54-of-benefits-plan-members-currently-live-with-at-least-one-chronic-condition-survey/ Tue, 19 Sep 2023 13:00:35 +0000 https://www.benefitscanada.com/?p=143610 More than half (54 per cent) of Canadian benefits plan members currently live with at least one diagnosed chronic health condition, according to the 2023 Benefits Canada Healthcare Survey. It found the top current diagnoses were a mental-health condition such as depression or anxiety (18 per cent), high cholesterol (12 per cent), arthritis (12 per […]

The post 54% of benefits plan members currently live with at least one chronic condition: survey appeared first on Benefits Canada.com.

]]> Gene, cell therapies raising questions of drug cost responsibilities: expert https://www.benefitscanada.com/benefits/health-benefits/gene-cell-therapies-raising-questions-of-drug-cost-responsibilities-expert/ Fri, 21 Jul 2023 13:00:30 +0000 https://www.benefitscanada.com/?p=141260 The growth of gene and cell therapies are raising significant questions among private payers about who bears the responsibility for the costs of these treatments, says Tim Clarke, president at TC Health Consulting Inc. “One issue is whether this is going to be paid for by public health or if it’s an employer health issue. […]

The post Gene, cell therapies raising questions of drug cost responsibilities: expert appeared first on Benefits Canada.com.

]]> Specialty drugs accounting for smaller portion of total eligible claims amount: report https://www.benefitscanada.com/benefits/health-benefits/specialty-drugs-accounting-for-smaller-portion-of-total-eligible-claims-amount-report/ Wed, 14 Jun 2023 19:00:17 +0000 https://www.benefitscanada.com/?p=139815 Specialty drugs are accounting for a slightly smaller portion of the total eligible amount for all drug claims, declining from 33.6 per cent in 2021 to 33.1 per cent in 2022, according to Telus Health’s annual drug trends report. The report, based on claims data from more than 4.6 million plan members in 2022, found the […]

The post Specialty drugs accounting for smaller portion of total eligible claims amount: report appeared first on Benefits Canada.com.

]]> Annual spend per private drug plan member up 6.3% in 2022: report https://www.benefitscanada.com/benefits/health-benefits/annual-spend-per-private-drug-plan-member-up-6-3-in-2022-report/ Thu, 20 Apr 2023 13:00:23 +0000 https://www.benefitscanada.com/?p=136809 The annual spend per private drug plan member increased by 6.3 per cent in 2022, according to Express Scripts Canada’s annual drug trends report. Across both traditional and specialty drugs, the increase was primarily driven by a 5.4 per cent rise in plan members making a claim, which reversed the trend seen in 2020 and […]

The post Annual spend per private drug plan member up 6.3% in 2022: report appeared first on Benefits Canada.com.

]]>